Health
ADHD affects 1 in 9 kids in US, new report reveals: ‘Shame and stigma’
Diagnoses of ADHD continue to rise among U.S. youth, affecting one in every nine U.S. kids.
Approximately 11.4% of U.S. children (7.1 million) have received an ADHD diagnosis at some point, and 10.5% (6.5 million) currently have the disorder, according to a study from the Centers for Disease Control and Prevention (CDC).
Researchers analyzed data from the 2022 National Survey of Children’s Health (NSCH), which measured the prevalence of attention-deficit/hyperactivity disorder diagnoses among kids between 3 and 17 years of age.
MENTAL HEALTH MAY BE WORSE IN TEENS FROM LARGE FAMILIES, STUDY SUGGESTS: ‘FEWER RESOURCES’
The study was published in the Journal of Clinical Child & Adolescent Psychology on May 22.
“Pediatric ADHD remains an ongoing and expanding public health concern, as approximately one million more children had ever received an ADHD diagnosis in 2022 than in 2016,” the researchers wrote.
Diagnoses of ADHD continue to rise among U.S. youth, affecting one in every nine U.S. kids, a new report revealed. (iStock)
Among the children who currently have the disorder, more than 58% have moderate or severe ADHD, and nearly 78% have at least one other disorder, the study found.
Around half of the children are taking some form of medication for their ADHD, and nearly 45% have received behavioral treatment in the past year.
ADHD IN MALES VERSUS FEMALES: WHAT YOU MUST KNOW ABOUT THE DIFFERENCES IN SYMPTOMS AND TREATMENTS
Just over 30% had not received any treatment for ADHD, the study also found.
“The prevalence of diagnosed ADHD varies by sociodemographic factors,” the researchers wrote.
“It is more common in boys, children living in lower-income households, children with public health insurance and children living in rural areas.”
Why the rise in ADHD?
Dr. Tasha M. Brown, a New York child psychologist and owner and founder of TMB Psych Services, said the findings did not surprise her.
“There is so much more conversation around mental health and what symptoms of ADHD look like,” Brown, who was not involved in the study, told Fox News Digital.
Among the children who currently have the disorder, more than 58% have moderate or severe ADHD, and nearly 78% have at least one other disorder, the new study found. (iStock)
“As a result, I think parents and caregivers are more aware of what to look for, and they are reaching out to providers for answers and a diagnosis sooner rather than later.”
There are also many more factors affecting children’s mental health, Brown said — “especially dealing with the impact the pandemic has had on schooling, activities and friendships … As a result, we are seeing more children presenting with hyperactivity and attention and impulsivity.”
NAVIGATING 2024 WITH STRATEGIES TAILORED FOR THOSE SUFFERING FROM ANXIETY, DEPRESSION, ADHD
Lisa Sheinhouse, director of community programs at Ohel Children’s Home and Family Services in New York, agreed that there is more awareness and education about neurodivergent disorders like ADHD and autism.
“Our society has learned to let go of the shame and stigma around these diagnoses, and that’s empowered parents to become more informed and ask for help,” Sheinhouse, who was also not involved in the study, told Fox News Digital.
What can parents and families do?
For parents who have children with ADHD, it is important to think about the ways in which their child’s ADHD symptoms are impacting their overall functioning, Brown said.
“For many children, symptoms of impulsivity, inattention and/or hyperactivity significantly impact their functioning in the school setting,” she noted.
For parents who have children with ADHD, it is important to think about the ways in which their child’s ADHD symptoms are impacting their overall functioning, an expert said. (iStock)
“Therefore, I advise parents to check in with teachers to make sure their child is receiving the appropriate accommodations in the classroom setting.”
Parents should also focus on creating and maintaining structure in the home and supporting ongoing routines for a child with ADHD, Sheinhouse added.
“Pediatric ADHD remains an ongoing and expanding public health concern.”
“This is important because a child with ADHD can be triggered by plans suddenly changing, especially without explanation,” she told Fox News Digital.
“You can teach your child executive functional skills like time management and provide tools (like apps) to help them remember things, stay on time and feel independent.”
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
Medication isn’t always necessary and shouldn’t be the first solution, according to Sheinhouse.
“However, never say never, because sometimes it’s something to consider to give your child better function. Medication is another tool in the toolbox and should be a personal decision based on the child.”
Medication isn’t always necessary and shouldn’t be the first solution, according to one expert, but is “something to consider to give your child better function.” (iStock)
While medication management can be a “game changer” for some kids with ADHD, Brown noted, it can be a “hard decision” for parents.
“We do know that the research is clear that medication management in combination with mental health treatment is the most effective,” she said.
“I advise parents to speak with a psychiatrist who specializes in working with children and adolescents about their medication management options.”
Overall, Brown said, early intervention is key to helping kids thrive.
“If parents think that their child is struggling with attentional difficulties, it is crucial that they reach out for support,” she said.
Fox News Digital reached out to the study authors requesting further comment.
For more Health articles, visit www.foxnews.com/health.
NEWYou can now listen to Fox News articles!
During a recent episode of her podcast, Gwyneth Paltrow spoke with neuroscientist Dr. Andrew Huberman about retatrutide, a new advancement in GLP-1 (glucagon-like peptide-1) therapies.
In recent years, GLP-1 receptor agonists have become a major focus in discussions around biohacking, longevity and wellness – but they’re not without a multitude of side effects.
Huberman noted that while first-generation weight-loss drugs curbed users’ appetites, they frequently plunged them into massive, rapid caloric deficits.
‘NEXT OZEMPIC’ AIMS TO DELIVER 30% WEIGHT LOSS WITH FEWER SIDE EFFECTS
Without aggressive resistance training, a high percentage of that lost weight came directly from lean muscle. “People would lose a ton of weight, but they would also lose muscle mass,” Huberman told Paltrow.
In clinical trials, retatrutide is administered as a once-weekly subcutaneous injection. (iStock)
That is where retatrutide comes in, he said. Unlike older single- or dual-action medications, retatrutide is a triple agonist.
That means it activates the body’s receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon – three hormones involved in regulating blood sugar, appetite and metabolism.
WEIGHT-LOSS EXPERTS PREDICT 5 MAJOR TREATMENT CHANGES LIKELY TO EMERGE IN 2026
“Retatrutide is a more mild agonist of GLP-1,” said Huberman. “It also increases glucagon and … GIP. So, it hits three different pathways, each a bit more subtly.”
In clinical trials, retatrutide is administered as a once-weekly subcutaneous injection.
Without aggressive resistance training, a high percentage of lost weight can come directly from lean muscle mass, said Andrew Huberman. (iStock)
Because of its balanced, multi-receptor approach, Huberman said the drug has a “lower side effect profile” while still allowing people to lose up to a third of their body weight “across a year or so.”
NEW OZEMPIC-ALTERNATIVE DIABETES PILL BURNS FAT WITHOUT MUSCLE LOSS, STUDY SUGGESTS
Most importantly for fitness and longevity advocates, the doctor pointed out that retatrutide seems to have “some muscle sparing effect.”
Because the drug is still moving through official pipelines, a massive gray market of compounding pharmacies and online peptide suppliers has cropped up to meet the growing demand.
Retatrutide is an investigational molecule that is legally available only to participants in Lilly’s clinical trials, according to Lilly’s website, and the company is currently “evaluating its safety and efficacy” in these clinical studies. (iStock)
Huberman issued a strict warning regarding these unregulated online sources, noting that these options “can say 99% purity, but that 1% means there could be some LPS,” referring to lipopolysaccharides, a type of bacterial toxin.
CLICK HERE FOR MORE HEALTH STORIES
“LPS will cause inflammation,” he cautioned. “One injection isn’t gonna do it, but multiple injections over time, I could see where that could become problematic.”
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
Paltrow echoed the safety concerns, comparing the current “wild-west” peptide craze to the landscape of supplements in the 90s, “where there’s really no third-party testing and it’s kind of word of mouth.”
“Multiple injections over time, I could see where that could become problematic.”
Both agreed that anyone exploring these therapies should avoid unverified online sources and prioritize working with a medical doctor.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
Retatrutide is an investigational molecule that is legally available only to participants in Lilly’s clinical trials, according to the manufacturer’s website. The company is currently “evaluating its safety and efficacy.”
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
The drug has not been reviewed or approved by any regulatory agency, and no one should consider taking anything claiming to be retatrutide outside of a Lilly-sponsored clinical trial, experts advise.
Use left and right arrow keys to navigate between menu items.
Use escape to exit the menu.
Sign Up
Create a free account to access exclusive content, play games, solve puzzles, test your pop-culture knowledge and receive special offers.
Already have an account? Login
NEWYou can now listen to Fox News articles!
A new treatment for endometrial cancer demonstrated strong potential in a Phase 3 clinical trial.
Drugmaker Merck announced Monday that the investigational drug sacituzumab tirumotecan (sac-TMT) met its “primary endpoints” of overall survival and progression-free survival in patients with advanced or recurrent endometrial cancer.
The TroFuse-005 trial is the first global Phase 3 trial to “demonstrate statistically significant improvement” in survival compared to chemotherapy in these patients, according to a Merck press release.
WEIGHT-LOSS DRUGS NOW LINKED TO CANCER PROTECTION IN WOMEN, MAJOR NEW STUDY REVEALS
This was also the first and only antibody-drug conjugate (ADC) to achieve such a result for endometrial cancer patients in this setting, the researchers stated.
An ADC is a targeted cancer therapy that delivers more of the drug to tumor cells while limiting damage to healthy cells.
The investigational drug, sac-TMT, is administered every two weeks via IV infusion. (iStock)
The trial involved 776 patients with endometrial cancer whose disease worsened after receiving both platinum chemotherapy and immunotherapy.
The patients were randomly assigned sac-TMT, administered every two weeks, or a treatment of the physician’s choice, including doxorubin or paclitaxel chemotherapy. The patients were aware of which treatment they were receiving.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
Those receiving sac-TMT showed “clinically meaningful improvement” in their disease state compared to the treatment of physician’s choice, the researchers found.
The study also met response rate benchmarks and exhibited similar side effects to earlier studies of the same drug, Merck reported.
NEW BREAST CANCER DRUG WINS FDA APPROVAL AFTER SLASHING PROGRESSION RISK BY NEARLY 40%
The drugmaker did not disclose any statistics on exact survival benefit, response rate, side effect rates or other details, but the researchers aim to present this Phase 3 data at an upcoming medical meeting.
The drug “may be able to address a critical unmet need for certain patients with advanced endometrial cancer,” said the lead researcher (not pictured). (iStock)
Dr. Domenica Lorusso, the study’s global lead investigator and professor of obstetrics and gynecology at Humanitas University and Humanitas San Pio X in Milan, wrote in a press release that these results show sac-TMT “may be able to address a critical unmet need for certain patients with advanced endometrial cancer, one of the only cancers increasing in both incidence and mortality worldwide.”
CLICK HERE FOR MORE HEALTH STORIES
“Despite recent advances, patients whose disease progresses following treatment with platinum and immunotherapy are urgently in need of new options, and these findings show for the first time that a TROP2 ADC may be an effective option in this setting,” she added.
Dr. Brian Slomovitz, co-director of gynecologic oncology at Mount Sinai and an investigator on this trial, reflected on the study findings during an interview with Fox News Digital.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
“Unlike many other cancers that we are treating, the number of endometrial cancers and the number of deaths due to endometrial cancers are on the rise,” Slomovitz noted.
“In the United States, the number of deaths due to endometrial cancer has surpassed the number of deaths due to ovarian cancer, [making it] the deadliest of all gynecologic malignancies.”
Endometrial cancer has become “the deadliest of all gynecologic malignancies,” one doctor shared. (iStock)
Despite recent advancements introducing immunotherapy as the standard of care, “better treatment options” for patients with recurrent disease “remains an unmet need,” Slomovitz commented.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
“If the full data confirm this announcement, the key questions will be the magnitude of the survival benefit and the toxicity profile — those will define sac-TMT’s role,” he said.
“But an overall survival improvement in recurrent disease is a real, meaningful result for patients and their families, not just a statistical one.”
-
Los Angeles, Ca1 hour ago2 red-tailed hawk nestlings rescued after 63-foot fall in Santa Clarita
-
Detroit, MI1 hour agoFormer Detroit Mayor Mike Duggan drops out of Michigan governor race
-
San Francisco, CA2 hours agoSan Francisco Sheriff discusses security at houses of worship, pickpocket arrests
-
Dallas, TX2 hours ago3 Dallas Cowboys UDFAs Who Could Steal a Spot on 53-Man Roster
-
Miami, FL2 hours agoMan accused of following woman in his Tesla, exposing himself to her in South Miami
-
Boston, MA2 hours agoWhat’s happening in and around Boston during the World Cup
-
Denver, CO2 hours agoDenver weather: More sunshine, high plains storms
-
Seattle, WA2 hours agoThe Status of Fare Evasion in Washington State
